On Wednesday, Leerink Partners adjusted its stock price target on Incyte (NASDAQ:INCY) Corporation (NASDAQ:INCY), increasing it to $87 from the previous $85, while maintaining an Outperform rating on the stock. The revision followed Incyte's third-quarter 2024 financial report, which revealed that the company had surpassed analysts' revenue expectations for key products.
Incyte announced that its Jakafi sales reached approximately $741 million, exceeding the consensus forecast of $716 million by about 4%. This figure marked a roughly 5% increase from the previous quarter and a 16% rise year over year.
The company attributed the sales beat to patient growth across all indications for Jakafi. As a result, Incyte has raised the lower end of its full-year Jakafi revenue guidance to between $2.74 billion and $2.77 billion, up from the prior range of $2.71 billion to $2.75 billion, marking the second upward revision this year.
The company's Opzelura sales also outperformed expectations, coming in at around $139 million, about 7% higher than the consensus estimate of $131 million. Prescription volume growth contributed to a roughly 14% quarter-over-quarter increase in Opzelura sales. Overall, Incyte's total revenue for the quarter was approximately $1.14 billion, surpassing the consensus estimate of around $1.08 billion.
Despite the strong revenue performance, Incyte's net income of about $106 million and earnings per share (EPS) of $0.55 fell short of the consensus estimates of approximately $150 million and $0.84, respectively. The discrepancy was primarily due to higher expenses from the fair value of contingent consideration, mainly influenced by foreign exchange impacts on Iclusig, amounting to $23 million.
Moreover, the company's financials included a $100 million milestone payment to Macrogenics that was not part of the previous full-year 2024 guidance, potentially leading to a mismatch with many sell-side models.
Leerink Partners has updated its model for Incyte based on these results, leading to the decision to raise the price target while reiterating the Outperform rating.
In other recent news, Incyte Corporation has been the subject of several major developments. In their third-quarter report for 2024, the biopharmaceutical company showed significant revenue growth, driven mainly by its flagship products, Jakafi and Opzelura.
Incyte's management has also upgraded its full-year 2024 guidance for Jakafi sales to a range of $2.74 to $2.77 billion, a revision attributed to a surge in patient demand across all approved indications for the drug.
Investment banking firms Citi and Jefferies maintained a Buy rating on Incyte, with Citi increasing the stock's price target to $97 from $92, and Jefferies revising its price target to $84 from $81. BofA Securities also adjusted its stance on Incyte, shifting the rating to Buy from a previous Neutral and increasing the price target to $90 from $68. However, Truist Securities downgraded the stock from Buy to Hold due to concerns over the impending patent expiration for Jakafi.
Incyte's pipeline is under the spotlight, with multiple data readouts expected by the end of 2024 and into the first half of 2025. The company is preparing to release bioequivalence data for an extended-release version of Jakafi and results from studies targeting various inflammatory skin diseases and lymphomas are highly anticipated.
Moreover, Oppenheimer maintained its Outperform rating on Incyte, highlighting the potential impact of the company's pipeline programs and upcoming milestones.
InvestingPro Insights
Following Incyte Corporation's (NASDAQ:INCY) strong third-quarter performance and Leerink Partners' upward revision of its price target, InvestingPro data offers additional context to the company's financial position. Incyte's market capitalization stands at $14.18 billion, reflecting its significant presence in the biotechnology sector. The company's revenue for the last twelve months as of Q2 2024 reached $3.86 billion, with a notable growth rate of 9.78%, aligning with the positive sales trends reported in the article.
InvestingPro Tips highlight that Incyte holds more cash than debt on its balance sheet, which could provide financial flexibility for future research and development initiatives or potential acquisitions. This strong cash position is particularly relevant given the company's recent milestone payment to Macrogenics and its ongoing investment in product development.
Another InvestingPro Tip notes that management has been aggressively buying back shares, which may signal confidence in the company's future prospects. This aligns with the positive outlook suggested by the raised revenue guidance for Jakafi and the strong performance of Opzelura.
It's worth noting that InvestingPro offers 14 additional tips for Incyte, providing investors with a more comprehensive analysis of the company's financial health and market position. These insights can be particularly valuable for those looking to make informed decisions based on the latest financial data and expert analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.